Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy

被引:107
|
作者
Lin, G. [1 ]
Nishimura, R. A. [1 ]
Gersh, B. J. [4 ]
Phil, D. [1 ]
Ommen, S. R. [1 ]
Ackerman, M. J. [2 ,3 ]
Brady, P. A. [1 ]
机构
[1] Mayo Clin, Div Cardiovasc Dis, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Med, Rochester, MN 55905 USA
[3] Mayo Clin, Div Pediat Cardiol, Rochester, MN 55905 USA
[4] Mayo Clin, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA
关键词
SUDDEN CARDIAC DEATH; RISK; PREVENTION; THERAPY; DETERMINANTS; MYECTOMY;
D O I
10.1136/hrt.2008.150656
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Although the benefit of implantable cardioverter defibrillator (ICD) therapy in patients with hypertrophic cardiomyopathy (HCM) at risk for sudden cardiac arrest is well established, there may be a higher risk for device complications and inappropriate shocks. Objectives: To determine the incidence of inappropriate ICD shocks and device complications in HCM patients and the impact of young age at ICD implant and atrial fibrillation. Methods: HCM patients who underwent ICD implantation between January 1988 and December 2005 were included. The frequency of device complications, including pneumothorax, pericardial effusion, haematoma, lead revisions, infection and rate of inappropriate shocks, was determined. ICD shocks were characterised as inappropriate if triggered by sinus tachycardia, atrial fibrillation or device malfunction. Results: A total of 181 patients were included (mean age 44 (SD 17) years; 62% males). During a mean follow-up of 59 (42) months (4.92 years; 830.75 patient-years), 65 patients (36%) had a total of 88 device complications, including 42 (23%) patients with inappropriate shocks. The rate of inappropriate shocks was 5.3% per year (vs 4% risk of appropriate shocks), and the likelihood of inappropriate ICD shocks per 100 patient-years was 5.1. Younger age and atrial fibrillation were associated with an increased risk of inappropriate ICD discharges. Conclusions: The rate of inappropriate ICD shocks and frequency of device complications in HCM patients are not insignificant and are most common in younger patients and those with atrial fibrillation. Inappropriate ICD shocks are the most common device complication and should be accounted for when counselling high-risk HCM patients for ICD implantation.
引用
收藏
页码:709 / 714
页数:6
相关论文
共 50 条
  • [41] Shocks after implantable cardioverter-defibrillator implantation in idiopathic cardiomyopathy patients: a myocardial biopsy study
    Safak, Erdal
    D'Ancona, Giuseppe
    Schultheiss, Heinz-Peter
    Kuehl, Uwe
    Kische, Stephan
    Kaplan, Hilmi
    Ince, Hueseyin
    Ortak, Jasmin
    HEART AND VESSELS, 2018, 33 (02) : 205 - 211
  • [42] The Healthcare Utilization and Cost of Treating Patients Experiencing Inappropriate Implantable Cardioverter Defibrillator Shocks: A Propensity Score Study
    Bhavnani, Sanjeev P.
    Giedrimiene, Dalia
    Coleman, Craig I.
    Guertin, Danette
    Azeem, Meena
    Kluger, Jeffrey
    PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2014, 37 (10): : 1315 - 1323
  • [43] Utilization and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Hypertrophic Cardiomyopathy
    Goldstein, Sarah A.
    Kennedy, Kevin F.
    Friedman, Daniel J.
    Al-Khatib, Sana M.
    Wang, Andrew
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2023, 12 (16):
  • [44] Living with hypertrophic cardiomyopathy and an implantable defibrillator
    Magnusson, Peter
    Jonsson, Jessica
    Morner, Stellan
    Fredriksson, Lennart
    BMC CARDIOVASCULAR DISORDERS, 2017, 17
  • [45] Statins Reduce Appropriate Implantable Cardioverter-Defibrillator Shocks in Ischemic Cardiomyopathy With no Benefit in Nonischemic Cardiomyopathy
    Contractor, Tahmeed
    Beri, Abhimanyu
    Gardiner, Joseph
    Ardhanari, Sivakumar
    Thakur, Ranjan
    AMERICAN JOURNAL OF THERAPEUTICS, 2012, 19 (06) : 413 - 418
  • [46] Complications of implantable cardioverter-defibrillator treatment in arrhythmogenic right ventricular cardiomyopathy
    Christensen, Alex Horby
    Platonov, Pyotr G.
    Svensson, Anneli
    Jensen, Henrik K.
    Rootwelt-Norberg, Christine
    Dahlberg, Pia
    Madsen, Trine
    Frederiksen, Tanja Charlotte
    Helio, Tiina
    Haugaa, Kristina H.
    Bundgaard, Henning
    Svendsen, Jesper H.
    EUROPACE, 2022, 24 (02): : 306 - 312
  • [47] Implantable Cardioverter-defibrillator Therapy for Hypertrophic Cardiomyopathy: Usefulness in Primary and Secondary Prevention
    Sarrias, Axel
    Galve, Enrique
    Sabate, Xavier
    Moya, Angel
    Anguera, Ignacio
    Nunez, Elaine
    Villuendas, Roger
    Alcalde, Oscar
    Garcia-Dorado, David
    REVISTA ESPANOLA DE CARDIOLOGIA, 2015, 68 (06): : 492 - 496
  • [48] Procedure- and device-related complications and psychological morbidity in implantable cardioverter defibrillator patients
    Pedersen, Susanne S.
    Hoogwegt, Madelein T.
    Jordaens, Luc
    Theuns, Dominic A. M. J.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (01) : 606 - 607
  • [49] Appropriate Implantable Defibrillator Therapy in Adults With Hypertrophic Cardiomyopathy
    Thavikulwat, Amalie C.
    Tomson, Todd T.
    Knight, Bradley P.
    Bonow, Robert O.
    Choudhury, Lubna
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2016, 27 (08) : 953 - 960
  • [50] Implantable cardioverter defibrillators in patients with electrical heart disease and hypertrophic cardiomyopathy: data from the German device registry
    Frommeyer, Gerrit
    Reinke, Florian
    Andresen, Dietrich
    Kleemann, Thomas
    Spitzer, Stefan G.
    Jehle, Joachim
    Brachmann, Johannes
    Stellbrink, Christoph
    Hochadel, Matthias
    Senges, Jochen
    Eckardt, Lars
    CLINICAL RESEARCH IN CARDIOLOGY, 2020, 109 (04) : 508 - 512